Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer_journal/the-glp-1-analogue-lixisenatide-decreases-atherosclerosis-in-insulin-FZeMYuUREJ
References (41)
-
J. Ussher, D. Drucker (2014)
Cardiovascular actions of incretin-based therapies.Circulation research, 114 11
-
D. Drucker (2006)
The biology of incretin hormones.Cell metabolism, 3 3
-
Yi Jin, Yusen Liu, L. Nelin (2014)
Extracellular Signal-regulated Kinase Mediates Expression of Arginase II but Not Inducible Nitric-oxide Synthase in Lipopolysaccharide-stimulated Macrophages*The Journal of Biological Chemistry, 290
-
Philip Larsen, Christian Fledelius, L. Knudsen, M. Tang-Christensen (2001)
Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.Diabetes, 50 11
-
Distribution of macrophage polarization markers in human -
Y. Tashiro, Kengo Sato, Takuya Watanabe, K. Nohtomi, Michishige Terasaki, Masaharu Nagashima, T. Hirano (2014)
A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosisPeptides, 54
-
M. Noyan-Ashraf, E. Shikatani, I. Schuiki, I. Mukovozov, Jun Wu, Ren-Ke Li, A. Volchuk, L. Robinson, F. Billia, D. Drucker, M. Husain (2013)
A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of ObesityCirculation, 127
-
Julia Baumgartl, S. Baudler, M. Scherner, V. Babaev, L. Makowski, J. Suttles, M. Mcduffie, K. Tobe, T. Kadowaki, S. Fazio, C. Kahn, G. Hotamışlıgil, W. Krone, M. Linton, J. Brüning (2006)
Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis.Cell metabolism, 3 4
-
Seongah Han, Chien-ping Liang, Tracie DeVries-Seimon, M. Ranalletta, C. Welch, Kadesha Collins-Fletcher, D. Accili, I. Tabas, A. Tall (2006)
Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions.Cell metabolism, 3 4
-
P. Ridker, T. Lüscher (2014)
Anti-inflammatory therapies for cardiovascular disease.European heart journal, 35 27
-
N. Krasner, Y. Ido, N. Ruderman, José Cacicedo (2014)
Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent MechanismPLoS ONE, 9
-
K. Bornfeldt (2015)
Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award LectureDiabetes, 64
-
白木 綾 (2012)
The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells -
H. González-Navarro, Á. Vinué, M. Sanz, M. Delgado, M. Pozo, M. Serrano, D. Burks, V. Andrés (2013)
Increased dosage of Ink4/Arf protects against glucose intolerance and insulin resistance associated with agingAging Cell, 12
-
P. Maurovich-Horvat, M. Ferencik, S. Voros, B. Merkely, U. Hoffmann (2014)
Comprehensive plaque assessment by coronary CT angiographyNature Reviews Cardiology, 11
-
P. Wohlfart, W. Linz, T. Hübschle, D. Linz, Jochen Huber, S. Hess, D. Crowther, U. Werner, H. Ruetten (2013)
Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studiesJournal of Translational Medicine, 11
-
Á. Vinué, I. Andrés-Blasco, A. Herrero-Cervera, L. Piqueras, V. Andrés, D. Burks, M. Sanz, H. González-Navarro (2015)
Ink4/Arf locus restores glucose tolerance and insulin sensitivity by reducing hepatic steatosis and inflammation in mice with impaired IRS2-dependent signalling.Biochimica et biophysica acta, 1852 9
-
Xu-ping Wang, Wei Zhang, Xiaoqiong Liu, Wen-ke Wang, Fei Yan, Wen-qian Dong, Yun Zhang, Ming-Xiang Zhang (2014)
Arginase I enhances atherosclerotic plaque stabilization by inhibiting inflammation and promoting smooth muscle cell proliferation.European heart journal, 35 14
-
M. Arakawa, T. Mita, K. Azuma, C. Ebato, Hiromasa Goto, T. Nomiyama, Y. Fujitani, T. Hirose, R. Kawamori, H. Watada (2010)
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4Diabetes, 59
-
R. Dijk, A. Duinisveld, A. Schaapherder, A. Mulder-Stapel, J. Hamming, J. Kuiper, O. Boer, A. Wal, F. Kolodgie, R. Virmani, J. Lindeman (2015)
A Change in Inflammatory Footprint Precedes Plaque Instability: A Systematic Evaluation of Cellular Aspects of the Adaptive Immune Response in Human AtherosclerosisJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 4
-
Daisuke Shiraishi, Yukio Fujiwara, Y. Komohara, H. Mizuta, M. Takeya (2012)
Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation.Biochemical and biophysical research communications, 425 2
-
L. Bisgaard, M. Bosteen, L. Fink, C. Sørensen, A. Rosendahl, C. Mogensen, S. Rasmussen, B. Rolin, L. Nielsen, Tanja Pedersen (2016)
Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- MicePLoS ONE, 11
-
Yao Dai, J. Mehta, Mingwei Chen (2013)
Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B ActivationCardiovascular Drugs and Therapy, 27
-
I. Andrés-Blasco, Á. Vinué, A. Herrero-Cervera, S. Martínez-Hervás, L. Núñez, L. Piqueras, J. Ascaso, M. Sanz, D. Burks, H. González-Navarro (2016)
Hepatic lipase inactivation decreases atherosclerosis in insulin resistance by reducing LIGHT/Lymphotoxin β-Receptor pathwayThrombosis and Haemostasis, 116
-
M. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H. Gerstein, L. Køber, Francesca Lawson, Lin Ping, Xiaodan Wei, E. Lewis, A. Maggioni, J. McMurray, J. Probstfield, M. Riddle, S. Solomon, J. Tardif (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.The New England journal of medicine, 373 23
-
S. Martorell, L. Hueso, H. González-Navarro, Aida Collado, M. Sanz, L. Piqueras (2016)
Vitamin D Receptor Activation Reduces Angiotensin-II–Induced Dissecting Abdominal Aortic Aneurysm in Apolipoprotein E–Knockout MiceArteriosclerosis, Thrombosis, and Vascular Biology, 36
-
T. Gaspari, I. Welungoda, R. Widdop, R. Simpson, A. Dear (2013)
The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse modelDiabetes & Vascular Disease Research, 10
-
C. Thorkildsen, S. Neve, B. Larsen, E. Meier, J. Petersen (2003)
Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db MiceJournal of Pharmacology and Experimental Therapeutics, 307
-
JL Stoger, MJ Gijbels, S Velden (2012)
Distribution of macrophage polarization markers in human atherosclerosisAtherosclerosis, 225
-
A. Sica, A. Mantovani (2012)
Macrophage plasticity and polarization: in vivo veritas.The Journal of clinical investigation, 122 3
-
H. González-Navarro, Z. Nong, M. Amar, R. Shamburek, Jamila Najib-Fruchart, B. Paigen, H. Brewer, S. Santamarina-Fojo (2004)
The Ligand-binding Function of Hepatic Lipase Modulates the Development of Atherosclerosis in Transgenic Mice*Journal of Biological Chemistry, 279
-
Luis Correia, Adriana Latado, Franz Porzsolt (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.The New England journal of medicine, 375 18
-
H. Kim, S. Tavakoli, L. Piefer, Huynh Nguyen, R. Asmis (2016)
Monocytic MKP-1 is a Sensor of the Metabolic Environment and Regulates Function and Phenotypic Fate of Monocyte-Derived Macrophages in AtherosclerosisScientific Reports, 6
-
S. Martínez-Hervás, Á. Vinué, L. Núñez, I. Andrés-Blasco, L. Piqueras, J. Real, J. Ascaso, D. Burks, M. Sanz, H. González-Navarro (2014)
Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis.Cardiovascular research, 103 2
-
H. González-Navarro, Y. Nabah, Á. Vinué, M. Andrés-Manzano, M. Collado, M. Serrano, V. Andrés (2010)
p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis.Journal of the American College of Cardiology, 55 20
-
M. Noyan-Ashraf, M. Momen, Kiwon Ban, A. Sadi, Yu-Qing Zhou, A. Riazi, L. Baggio, R. Henkelman, M. Husain, D. Drucker (2009)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in MiceDiabetes, 58
-
F. Zhuge, Y. Ni, M. Nagashimada, N. Nagata, Liang Xu, N. Mukaida, S. Kaneko, Tsuguhito Ota (2016)
DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage PolarizationDiabetes, 65
-
P. Libby, G. Pasterkamp (2015)
Requiem for the 'vulnerable plaque'.European heart journal, 36 43
-
Jonathan Campbell, D. Drucker (2013)
Pharmacology, physiology, and mechanisms of incretin hormone action.Cell metabolism, 17 6
-
U. Werner, G. Haschke, A. Herling, W. Kramer (2010)
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetesRegulatory Peptides, 164
-
H. González-Navarro, Marian Vila-Caballer, M. Pastor, Á. Vinué, M. White, D. Burks, V. Andrés (2007)
Plasma insulin levels predict the development of atherosclerosis when IRS2 deficiency is combined with severe hypercholesterolemia in apolipoprotein E-null mice.Frontiers in bioscience : a journal and virtual library, 12
- Publisher
- Springer Journals
- Copyright
- Copyright © 2017 by Springer-Verlag Berlin Heidelberg
- Subject
- Medicine & Public Health; Internal Medicine; Metabolic Diseases; Human Physiology
- ISSN
- 0012-186X
- eISSN
- 1432-0428
- DOI
- 10.1007/s00125-017-4330-3
- pmid
- 28608285
- Publisher site
- See Article on Publisher Site
Abstract
Diabetologia (2017) 60:1801–1812 DOI 10.1007/s00125-017-4330-3 ARTICLE The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype 1 1,2,3 1 1 Ángela Vinué & Jorge Navarro & Andrea Herrero-Cervera & Marta García-Cubas & 1 1,4,5 1,4,5 Irene Andrés-Blasco & Sergio Martínez-Hervás & José T. Real & 1,4,5 1,5 Juan F. Ascaso & Herminia González-Navarro Received: 25 January 2017 /Accepted: 10 May 2017 /Published online: 12 June 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract blood pressure but this was independent of body weight loss. Aims/hypothesis Recent clinical studies indicate that Both drugs significantly decreasedatheromaplaquesize. glucagon-like peptide-1 (GLP-1) analogues prevent acute car- Compared with vehicle-treated control mice, lixisenatide diovascular events in type 2 diabetes mellitus but their mech- treatment generated more stable atheromas, with fewer in- anisms remain unknown. In the present study, the impact of flammatory infiltrates, reduced necrotic cores and thicker fi- GLP-1 analogues and their potential underlying molecular brous caps. Lixisenatide-treated mice also displayed dimin- high mechanisms in insulin resistance and atherosclerosis are ished IL-6 levels, proinflammatory Ly6C monocytes and investigated. activated T cells. In vitro analysis showed that, in macro- −/− +/− Methods Atherosclerosis development was evaluated in phages from Apoe Irs2 mice, lixisenatide reduced the
Journal
Diabetologia – Springer Journals
Published: Jun 12, 2017